WuXi Advanced Therapies’ AAV TESSA Technology to be Licensed to Janssen

Anna Osborne
17 August 2022
SHARE NOW
Cell Therapy
Collaborations, Mergers & Acquisitions
Finance & Investment
Gene Therapy
Viral/Non-Viral Vectors
The Contract Testing, Development and Manufacturing Organization (CTDMO) WuXi Advanced Therapies (WuXi ATU), has announced that it will license its advanced AAV technology, TESSA, and its proprietary clonal suspension HEK293 cell line to Janssen Biotech, of Johnson & Johnson.

TESSA – Tetracycline-Enabled Self-Silencing Adenovirus – technology is a state-of-the-art novel process for GMP standard, scalable, and, transfection-free manufacture of adeno-associated viral (AAV) vectors, developed by WuXi ATU company OXGENE, in the UK.

“We are honored that Janssen selected WuXi ATU’s TESSA™ technology. We remain committed to improving the TESSA™ platform to produce faster and more cost effective AAV products for patients,” commented David Chang, CEO of WuXi Advanced Therapies.

 

WuXi’s TESSA system can successfully be scaled up to 200L, producing 10 times more AAV than traditional methods of AAV manufacturing, as well as resulting in a significantly higher percentage of full AAV capsids. This greatly reduces overall production costs in comparison to standard plasmid-based AAV systems.

How are you enjoying this news article? Let us know your thoughts, here >>

TESSA offers an efficient and cost-effective solution to meet industry demand for large-scale high-quality AAV manufacturing – delivering more accessible life-changing therapeutics to patients as quickly as possible.

Janssen will utilize TESSA’s applications for their own AAV production, and, HEK293 cell line for the research and development of its advanced therapies.

“The TESSA™ system is a game changer for the manufacture of AAV and the advancement of cell and gene therapies to benefit patients. By improving scalability, reducing process complexity and lowering the costs of gene therapy manufacture, TESSA™ will better enable our global partners to develop and deliver life-saving gene therapies faster to more patients in need,” Dr. Ryan Cawood, CSO of WuXi ATU, noted upon TESSA’s launch earlier this year.

Listen to Ryan Cawood explain more about TESSA in this Tech Demo.

Source: WuXi ATU Press Release


While we have you…

We are continuously working to better optimize our content for you, our audience. Let us know how we’re doing by ticking the box below, or send us your feedback directly to team@phacilitate.com.